Ondansetron
and droperidol are both effective prophylactic antiemetics for gynecologic outpatient procedures. However, increased drowsiness, delayed discharge, and postdischarge restlessness may occur with droperidol, and ondansetron is costly. In this prospective, randomized, double-blind, placebo-controlled study involving 161 women, we compared the efficacy, safety, and cost-effectiveness of ondansetron (4 mg intravenously [IV] ) with droperidol(O.625 mg or 1.25 mg IV) in the prevention of postoperative nausea and vomiting (PONV) after outpatient gynecologic surgery. The incidence of PONV, times to achieving preset recovery criteria, and patient-evaluated visual analog scales for sedation, anxiety, pain, and nausea were recorded, along with postdischarge emetic episodes, medications, quality of sleep, and time to resumption of food intake, normal activity, and return to work. A decision analysis tree was used to divide each data set into nine mutually exclusive subgroups, and costs and probabilities were assigned to each subgroup.
The costeffectiveness ratio was determined by summing these weighted costs and dividing by the number of patients free from both PONV and side effects of antiemetic therapy. The incidence of PONV in the hospital and after discharge, the need for rescue antiemetic therapy, and recovery and discharge times were similar for the ondansetron and both droperidol groups but differed significantly from those for the placebo group. The costeffectiveness ratios for both droperidol 0.625 mg and 1.25 mg groups were significantly lower than those for the ondansetron and placebo groups. We conclude that droperidol 0.625 mg IV provides antiemetic prophylaxis comparable to that of ondansetron 4 mg IV without increasing side effects or delaying discharge and is more cost-effective. (Anesth Analg 1996; 83:304-13) P o&operative nausea and vomiting (PONV) are common sequelae of general anesthesia and a leading cause of delayed discharge and unanticipated hospital admissions after ambulatory surgical procedures (1). The incidence of PONV after gynecological surgery is frequent, leading to the recommendation of "routine" prophylactic administration of antiemetics (e.g., droperidol, ondansetron, and metoclopramide) in this ambulatory surgery population (2). Droperidol is more effective than placebo in the prevention of PONV, but is associated with a relatively high incidence of extrapyramidal side effects and delayed awakening when larger doses (2.5 mg) are used (3, 4) . Smaller doses (1.25 mg) are effective but may be associated with restlessness (4). The efficacy of smaller doses of droperidol (Cl.25 mg) has not been well established. Ondansetron, a selective 5-HT, receptor antagonist, is more effective than placebo in the prevention and treatment of PONV (5, 6) . The lack of associated side effects makes the use of ondansetron attractive in the ambulatory surgery setting (7) . However, it is expensive compared with traditional antiemetics and may quickly consume a major portion of an anesthetic pharmacy budget (8) . In a recent editorial, Lerman has stated that "the most effective, longest acting, side effect free and least expensive" drug should be the antiemetic of choice (9).
In this prospective, randomized, double-blind, placebo-controlled, clinical study, we compared the efficacy, safety, and cost-effectiveness of ondansetron (4 mg) with two different doses of droperidol (0.625 mg and 1.25 mg) in the prevention of PONV after elective outpatient gynecologic procedures. 
Methods
After we obtained institutional review board approval and written, informed consent, 161 (ASA physical status I or II) female outpatients who were scheduled to undergo laparoscopic tubal ligation, cone biopsy, and diagnostic laparoscopy procedures were enrolled in this study. Patients who were pregnant, had received any other antiemetic or psychotropic medication within 24 h before surgery, were more than 100% over ideal body weight, or had vomiting or retching within 24 h prior to the study were excluded.
A medical history (including alcohol or drug consumption, previous motion sickness, prior PONV, and date of the last menstrual cycle) was recorded along with demographic information regarding age, weight, height, and ethnic origin. All patients completed baseline visual analog scales for nausea, sedation, anxiety, dizziness, and pain using a loo-mm scale (0 = none to 100 = maximum) before receiving midazolam 2 mg intravenously (IV) for preanesthetic sedation. Patients were randomized on the basis of a computergenerated random number to receive one of four prophylactic treatments: saline placebo, droperidol 0.625 mg, droperidol 1.25 mg, or ondansetron 4 mg. The study drug was prepared by the hospital pharmacy department in a fixed volume of 5 mL and administered IV over a 30 to 60 s interval after baseline blood pressure, heart rate, and pulse oximetry values were recorded. The patient, anesthesiologist, observers, and nurses were blinded to the study drug. Within 5 min after the study drug was administered, anesthesia was induced with thiopental, 3-5 mg/ kg IV, and fentanyl, l-2 pg/kg IV, and tracheal intubation was facilitated with succinylcholine (1 mg/kg IV) or rocuronium (0.6 mg/ kg IV). Anesthesia was maintained with fentanyl (0.5-l pg/ kg IV), 67% nitrous oxide (N,O) in oxygen, and 3%-6% desflurane.
Ketorolac, 30 mg IV and 30 mg intramuscularly, was administered prior to the end of surgery. If necessary, residual neuromuscular blockade was antagonized with edrophonium (0.5-l mg/kg IV) and atropine (0.6-1.2 mg IV) and the trachea was extubated when the patient was awake. In the immediate postanesthetic period, pain was managed with fentanyl. After discharge from the hospital, oral analgesics were administered as needed.
One of the investigators recorded the surgical time (from surgical incision to skin closure), anesthesia time (from start of induction to discontinuation of N,O), and the time at which the patient opened her eyes and was oriented, along with the duration of her stay in the postanesthesia care unit (PACU) and the time to oral intake, ambulation, and the achievement of predetermined discharge criteria. These criteria included stable vital signs, ability to ambulate, passage of urine, and absence of severe nausea or pain. At 30-min intervals after arrival in the PACU, patients assessed their nausea, sedation, anxiety, dizziness, and pain using a loo-mm visual analog scale as described above. In addition, the investigator recorded the time of actual discharge, all medications and resources used in the PACU, and the occurrence of any postoperative complications, including emetic episodes. An emetic episode was defined as vomiting or retching, and the episodes had to be separated by 1 min. Patients who continued to vomit or experienced persistent nausea lasting >15 min received metoclopramide lo-20 mg IV. If nausea or emesis persisted after the administration of metoclopramide, ondansetron 4 mg IV was administered.
The number of doses of "rescue antiemetics" was recorded along with the reason for antiemetic therapy. At 24 h and 7 days after surgery, patients were contacted by telephone to determine the number of emetic episodes, the overall nausea score, antiemetic and analgesic medications used, the quality of sleep, the time to first oral intake, resumption of normal food intake, activity, and return to work. We also inquired whether any person other than the patient had to take time off from work to assist the patient and whether any adverse events (e.g., would infection) had occurred or additional medical attention, such as a visit to the doctor's office or the emergency room, was needed.
A sample of size of 37 for each group was determined by power analysis prior to the start of the study. The power analysis was based on the following assumptions: (a) the incidence of PONV in the placebo group would be 65% (4); (b) a difference of 35% in the incidence of PONV would be considered of clinical importance, such that effective antiemetic prophylaxis would reduce PONV rates to 130% (5); and (c) QL = 0.05 and p = 0.2.
Statistical analyses of these data were performed by one-way analysis of a variance for continuous variables, and, when a significant difference was noted, post-hoc intergroup comparisons were performed using Scheffe's test. When appropriate, a Kruskal-Wallis test was also performed.
Categorical data were analyzed using the J$ test with Yates' correction and the Fisher's exact test. P values co.05 were considered statistically significant. Data are reported as mean 5 SD unless otherwise stated. For the cost-effectiveness analysis, the data set for each treatment group was partitioned according to a decision analysis tree (Fig. 1 ). The criteria for partitioning were based on the observed frequency of (a) PONV after prophylactic therapy, (b) the need for additional rescue antiemetic therapy despite prophylaxis, (c) the incidence of side effects of prophylactic and therapeutic antiemetic drugs, and (d) the need for hospital admission for the management of persistent emesis in spite of antiemetic therapy (10). Patients TANG ET AL. ANESTH ANALG COSTS AND EFFICACY OF SMALL-DOSE 1996;83:304-13 NO s,de effects atrat discharged TP7 ome Figure  1 . Decision analysis tree for dividing data sets into nine mutually exclusive subgroups.
The costs for each subgroup are assigned along with the probabilities of a patient reaching that end point. The sum of the weighted costs divided by the number of patients without postoperative emesis and the side effects of the antiemetic drugs gives the cost-effectiveness ratio. PONV = postoperative nausea and vomiting. could be divided into nine mutually exclusive subgroups, and the probability (and confidence limits) of a patient following a specific path was calculated. Direct and indirect costs for reaching a given end point in the decision analysis tree were assigned as indicated in the Appendix.
Direct costs for the management of emesis included costs for "emesis clean up," rescue antiemetic therapy, and management of side effects of prophylactic and rescue antiemetic therapy (Table 1) (10). Direct costs for the ondansetron and droperidol groups included the acquisition cost and materials used for administering prophylactic drugs, along with the incremental costs for the time, drugs, and materials used to manage emesis. The drug acquisition costs, prorated hourly nursing salary (with benefits), and nurse-patient ratios in the PACU and phase II recovery area were provided by the hospital administration.
The time spent by nurses (a) providing, emptying, and cleaning emesis basins, suction tubing, and Yankauer suckers; (b) providing mouth wash, comforting the patient, and changing patient linen and bed clothes after emesis; and (c) calling a physician, administering antiemetic drugs, and recording these events in the chart were noted. Emesis management costs prior to discharge included costs of resources used (e.g., emesis basin, washcloth, suction, bedclothes, drugs) along with nursing time (Table 1) . Costs for managing emesis after discharge from hospital were limited to costs of cleaning up emesis and costs of antiemetic drugs. Indirect costs included the costs to the patient and caretaker from lost wages and travel from the patient's home to the doctor's office or a hospital for the management of emesis after discharge from the ambulatory care facility. The costs for a caretaker were assumed to be equal to the earnings of a minimum wage worker. Costs were identified separately using the perspective of (a) the hospital in a managed care environment, (b) the department of anesthesia, (c) the insurance company, (d) the patient, and (e) society as a whole. For calculations based on the societal perspective, all direct and indirect costs were used (Table 2) . When the perspective was limited to that of the hospital in a managed care environment, the department of anesthesia, or the insurance company, indirect costs were excluded. Costs from the patient's perspective were limited to indirect costs and the costs of managing emesis after discharge from the hospital, as it was assumed that the patient's health insurance would pay for the other costs.
The probability of a patient reaching a given end point in the decision analysis tree was calculated by partitioning the data set. For example, 22 of 40 patients in the placebo group had emesis in hospital, while 18 did not. Hence, the probability of a patient following the "No PONV" path (TPl-3) in this group would be 0.45 (B/40) with a 95% confidence interval of 0.29-0.61. The product of the costs for this outcome and the probability of a patient reaching this end point provided the weighted cost for a specific outcome. The sum of these costs provided the weighted total costs associated with the use of a given antiemetic drug.
Cost-effectiveness ratios were calculated using financial costs as the numerator and therapeutic success as the denominator (Table 2) . Therapeutic success was defined as the number of patients free from both emesis and side effects of antiemetic drugs. Confidence values for these ratios were obtained using standard formulae. Data management and calculations were performed on an Excel 4.0 spreadsheet (Microsoft Corporation, Redmond, WA) using a Macintosh computer. Sensitivity analysis was performed to determine the effect of varying the probabilities used in partitioning data on the overall conclusions of the relative cost-efficacy of the two antiemetic drugs.
Results
There were no significant differences between the groups with respect to age, weight, height, day since last menstrual period, incidence of motion sickness, prior history of PONV, type and duration of surgery and anesthesia, or perioperative IV fluid administration (Table 3 ). There were also no significant differences between the four groups in the type and duration of surgery and anesthesia, including the use of nondepolarizing muscle relaxants and antagonists, perioperative opioids, and other analgesic medications. The time to tracheal extubation, eye opening, orientation, oral intake, and resumption of normal activity were similar in all four groups (Table 4 ). After discharge from the hospital, there were no significant differences in the quality of sleep, the time to resume oral liquids and solids, or the need for assistance by a caretaker ( Table 5 ). The duration of stay in the PACU was significantly longer in the placebo group compared with the droperidol (0.625 and 1.25 mg) and ondansetron groups but did not differ between the droperidol and ondansetron groups. The times to ambulation, achievement of discharge criteria, and time of actual discharge were not significantly different between the study groups (Table 4) .
During the first two postoperative hours, the number of patients who were "free" from nausea and emesis was significantly larger in the ondansetron and droperidol groups compared with the placebo group. The incidence of emesis and the need for rescue antiemetics was significantly lower in both droperidol and ondansetron groups compared with the placebo group (P < 0.05) but did not differ between the droperidol (0.625 and 1.25 mg) and ondansetron groups (Table 6) .
Follow-up data after discharge from the ambulatory surgery unit were available for 110 patients. The incidence of vomiting was significantly less frequent in the groups receiving droperidol 0.625 or 1.25 mg and ondansetron groups when compared with the placebo group. However, the incidence of nausea was only significantly different between the ondansetron and placebo (P < 0.05) groups. Among the three antiemetic treatment groups, there were no significant differences in the need for rescue antiemetics after discharge, or in the number of patients who received >l dose of rescue antiemetic medication during the first 24 h after discharge (Table 6 ). There were also no significant differences in the times to return of normal activity, in the need for a caretaker to assist in daily activities, or in the incidence of restlessness, drowsiness, or other untoward side effects between the four groups (Table 5) . No patient in the study was admitted to the hospital for the management of persistent emesis.
The costs per patient not experiencing PONV and free from the side effects of prophylactic antiemetic drugs (i.e., cost-effectiveness ratio) were $39.19 [95% confidence intervals (CI) $23.90~$75.371 for the placebo group, $8.39 (95% CI $6.52-$12.16) for the droperidol 0.625 mg group if it was assumed that no droperidol was wasted, and $11.93 (95% CI $9.28-$17.30) for this group if it was assumed that the remaining droperidol in a vial was wasted. The costeffectiveness ratio for the droperidol 1.25 mg group was $11.33 (95% CI $8.88-$16.66), assuming that no droperidol was wasted and $12.80 (95% CI $9.69-$18.82) assuming that remaining portion of droperidol was wasted. The cost-effectiveness ratios for both droperidol groups were significantly lower than for the placebo group but did not differ significantly ANESTH between the two droperidol groups. In contrast, the cost-effectiveness ratio for ondansetron was $28.49 (95% CI $23.44-$38.58), which was significantly greater than the cost-effectiveness ratio for either droperidol group (Table 2) . The conclusions regarding the relative costeffectiveness ratios were sensitive to the acquisition costs of ondansetron, the additional time spent by the patient in the PACU, the incidence of emesis prior to discharge from the ambulatory surgery center, and the rate of unanticipated admission for the management of persistent emesis. If the ratio of the acquisition cost of ondansetron to droperidol was 2.5:1 or less rather than the current 7:1, ondansetron would be more cost effective. Depending on the incidence of predischarge emesis, the prophylactic use of antiemetics was more cost-effective than the strategy of limiting their use to the management of established emesis. The cross-over point for the incidence of predischarge emesis, where prophylactic antiemetic therapy was more costeffective than its use in the PACU, was 13% for droperidol and 30% for ondansetron. If the use of droperidol was associated with a mean increase in the PACU (phase I recovery) stay for an additional 53 min, or in a phase II recovery stay for an additional 94 min, ondansetron would be more cost-effective from the institutional perspective in our model. From the perspective of the insurance company, the routine use of prophylactic ondansetron would be more costeffective than droperidol if the difference in admission rates for the management of emesis exceeded 1:3000 patients. From both a societal and the patients' perspective, ondansetron would be more cost-effective than droperidol if its use was associated with an earlier return to work by a mean of 0.8 days. However, we failed to demonstrate that the preferential use of ondansetron over droperidol was associated with any significant differences in times to discharge readiness ANESTHESIA TANG ET AL. ANESTH ANALG COSTS AND EFFICACY OF SMALL-DOSE EMESIS 1996; 83:304-13 from the PACU or the ambulatory surgery center, in the time to return to work, or in the need for a caretaker to assist the patient during the postdischarge recovery phase.
Discussion
This study has confirmed that ondansetron 4 mg IV and droperidol 1.25 mg IV are effective prophylactic antiemetics compared with placebo in women undergoing outpatient gynecological procedures.
The success rates in our study are similar to those in previously reported studies with these drugs (4, 5) . This study has also demonstrated that a smaller dose of droperidol, 0.625 mg, is as effective as ondansetron (4 mg) and larger doses of droperidol (1.25 mg) in preventing PONV in this outpatient population. Direct comparisons of ondansetron with droperidol in published studies have provided varying results. In one study, Alon and Himmelsehr (11) found ondansetron 8 mg IV to be more effective than droperidol 1.25 mg. However, in another study, this same group noted that ondanestron 4 mg IV was inferior to droperidol 1.25 mg IV in the prophylaxis of PONV in women undergoing gynecologic laparoscopy (12). Others have noted a similar efficacy of ondansetron 8 mg and droperidol 2.5 mg in women undergoing abdominal or gynecologic surgery (13, 14) . More recently, Paxton et al. (15) demonstrated that ondansetron 4 mg IV was a superior prophylactic antiemetic compared with both metoclopramide 10 mg IV and droperidol 1 mg IV in women undergoing outpatient gynecological surgery. However, other authors have noted a similar efficacy of prophylactic ondansetron 4 mg and droperidol 1.25 mg in inpatients after major orthopedic and gynecological procedures, while metoclopramide (10 mg) was no more effective than a placebo (16,17). Our results reporting a similar efficacy of ondansetron 4 mg and droperidoll.25 mg are consistent with the findings of Gan et al. (16) and Desilva et al. (17) .
The major concerns related to the use of droperidol in doses larger than those used in our study have been prolonged sedation, restlessness, and delayed recovery (3, 4, 15, 17) . These sedative effects have been alleged to be responsible for delayed discharge in pediatric outpatients receiving large doses of droperidol (50-75 pg/kg). In one study, Davis et al. (18) reported that ondansetron 0.1 mg/kg was more effective than droperidol 75 kg/kg in children undergoing dental surgery with a N,O-alfentanil anesthetic technique. These authors also reported that patients receiving ondansetron or placebo had shorter hospital stays than the droperidol group. In a similar study involving children undergoing adenotonsillectomy procedures, Splinter et al. (19) have demonstrated that ondansetron 150 pg/kg IV was more effective than droperidol50 pg / kg IV in preventing PONV and that it was also associated with an earlier discharge from the hospital. However, others have failed to demonstrate differences in discharge from the PACU in pediatric patients who received droperidol or ondansetron (20). Since the time of actual discharge from the hospital is dependent on a number of factors that are not related to the medical condition of the patient (e.g., completion of all paperwork, availability of the attending surgeon to discuss discharge instructions, availability of transportation home), it is more appropriate to examine the time to home-readiness rather than the time of actual discharge from the ambulatory surgery center. Alternatively, other early recovery end points (e.g., the time to eye opening, tracheal extubation, or ambulation) may be used. In our study, there were no significant differences between the study groups in the time to tracheal extubation, eye opening, orientation, ambulation, or AMBULATORY ANESTHESIA TANG ET AL.
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COSTS AND EFFICACY OF SMALL-DOSE DROPERIDOL VS ONDANSETRON IN PREVENTING EMESIS oral intake. However, the duration of stay in the PACU was significantly longer in the placebo group compared with the groups receiving ondansetron or droperidol.
Other authors have also found no differences in the time to orientation, ambulation, and discharge with small-dose droperidol compared with placebo, although recovery of psychomotor function may be delayed (21) . Another concern raised with the use of droperidol is delayed anxiety and restlessness after discharge (3). In this study, the sedation scores and patients' evaluation of their drowsiness did not differ between the groups while the patients were in hospital. We failed to detect any significant differences in the quality of sleep, the time to resume oral liquids and food intake, normal daily activity, or the need for assistance by a caretaker between the study groups after discharge from the ambulatory surgery center. However, the lower rate of successful follow-up by phone in our study compared with other studies may have contributed to our inability to detect differences in postdischarge restlessness. In keeping with the current movement toward "value-based" anesthetic care (22), we also examined the value associated with the use of prophylactic ondansetron, rather than concentrating on the surrogate end point of decreased emesis as the major factor in determining the utility of ondansetron in outpatient anesthesia (23). Since increased value can be obtained by achieving the same outcome at a lower cost or a better outcome at a higher cost (22), we examined the cost-efficacy of ondansetron and small-dose droperidol. We did not perform cost-minimization evaluations, as comparisons of acquisition costs of drugs without regard to the overall outcome or associated side effects are shortsighted and may not result in true cost savings. We also chose not to use hospital charges for drugs, but rather an estimate of actual costs in the comparisons, since there are major differences between costs and charges (24). In our analysis, small-dose droperidol (0.625 mg) was more costeffective than ondansetron.
These conclusions are sensitive to the assumptions used in our model, and other anesthesiology practitioners could use the model as a template to construct a cost-effectiveness evaluation that reflects practices in their own institutions.
In a recent editorial on the cost-effectiveness of antiemetic therapy, Lerman stated that "what may be heralded as a great therapeutic advance in one study may be simply a placebo effect in another! . . . the incidence of postoperative vomiting in your institution must be evaluated before you consider prophylactic antiemetic therapy for all . . . patients" (9). However, personnel costs constitute the major portion of costs associated with the delivery of anesthetic care (25) . PACU economics may be more affected by the peak number of patients admitted to the unit than by the choice of a prophylactic antiemetic agent (25).
From the perspective of the health care institution, personnel costs are semifixed, not variable, costs that alter with the amount of time spent by personnel in taking care of a problem (26) . Even if an extra 15-30 min is spent in the ambulatory care center, institutional costs are not affected unless there is a bottleneck in the flow of patients through the operating room suites or existing staff are required to work overtime or additional staff are hired. Pharmacoeconomic claims of a reduction in associated direct costs with the use of a drug must be subjected to the same scrutiny as any claims of scientific merit (27).
Finally, these cost-effectiveness analyses have not taken into consideration the preferences of the patient and have assumed that the value of avoiding emesis is the same as the value of avoiding the side effects of antiemetic therapy (28). There are suggestions that patients will tolerate some degree of pain, drowsiness, and delayed discharge to avoid postoperative nausea and vomiting.* However, there are also no data available to demonstrate that patients prefer the use of ondansetron to the older, less expensive antiemetic drugs, such as droperidol, dimenhydrinate, and perphenazine. These older drugs may have an antiemetic efficacy that is similar to ondansetron's.
Dimenhydrinate and perphenazine do not appear to be associated with the side effects of drowsiness and delayed discharge that have been reported with large-dose droperidol (9, 17) . In summary, this study has demonstrated that droperidol 0.625 mg IV is as effective as ondansetron 4 mg IV in the prophylaxis of PONV in women undergoing outpatient gynecologic surgery. In addition, small-dose droperidol may be more cost-effective than ondansetron as a prophylactic antiemetic based on the current acquisition costs. 
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